Information  X 
Enter a valid email address

Astrazeneca PLC OrdShs USD0.25 (AZN)

Date Time Source Announcement
15 Nov 2019 7:00 am
RNS
Qtrilmet approved in the EU for treatment of T2D
14 Nov 2019 7:00 am
RNS
FDA accepts regulatory submission for selumetinib
12 Nov 2019 7:00 am
RNS
Anifrolumab demonstrated superiority in TULIP 2
11 Nov 2019 7:00 am
RNS
Roxadustat pooled analyses: no increased CV risk
08 Nov 2019 7:00 am
RNS
Roxadustat significantly increased haemoglobin
06 Nov 2019 2:10 pm
RNS
Calquence data to show improved progression-free
01 Nov 2019 3:00 pm
RNS
Total Voting Rights
30 Oct 2019 7:00 am
RNS
AstraZeneca divests rights to Seroquel and
28 Oct 2019 3:31 pm
RNS
Imfinzi and Imfinzi plus tremelimumab delayed
24 Oct 2019 7:00 am
RNS
AstraZeneca year-to-date and Q3 2019 results
21 Oct 2019 7:00 am
RNS
Farxiga approved in the US to reduce the risk of
17 Oct 2019 7:00 am
RNS
Trastuzumab deruxtecan granted FDA Priority Review
04 Oct 2019 3:04 pm
RNS
Holding(s) in Company
  3:00 pm
RNS
Holding(s) in Company
  7:00 am
RNS
Fasenra approved in the US for self-administration
03 Oct 2019 4:00 pm
RNS
Director Declaration
01 Oct 2019 3:00 pm
RNS
Total Voting Rights
  7:05 am
RNS
AstraZeneca divests rights for Losec to Cheplaphar
  7:00 am
RNS
Update on US regulatory review of PT010 in COPD
30 Sep 2019 3:30 pm
RNS
Lynparza more than doubled the time without
  7:00 am
RNS
Tagrisso is the only 1st-line treatment for EGFR-
  7:00 am
RNS
Lynparza improved the time women lived without
23 Sep 2019 7:00 am
RNS
Qtrilmet recommended for approval in EU by CHMP
18 Sep 2019 7:00 am
RNS
AstraZeneca amends collaboration with Ironwood
09 Sep 2019 8:38 am
RNS
Imfinzi is first immunotherapy to show both
04 Sep 2019 7:11 am
RNS
Tagrisso approved in China as a 1st-line treatment
02 Sep 2019 3:00 pm
RNS
Total Voting Rights
  7:05 am
RNS
Brilinta reduced the risk of cardiovascular events
  7:00 am
RNS
Detailed results from Phase III DAPA-HF trial
29 Aug 2019 7:00 am
RNS
Anifrolumab Phase III trial meets primary endpoint
28 Aug 2019 7:05 am
RNS
Fasenra granted US Orphan Drug Designation for
  7:00 am
RNS
Breztri Aerosphere Phase III ETHOS trial met
22 Aug 2019 7:00 am
RNS
Roxadustat approved in China for the treatment of
  7:00 am
RNS
AstraZeneca agrees to buy US FDA Priority Review
21 Aug 2019 7:00 am
RNS
Update on the Phase III NEPTUNE trial
20 Aug 2019 7:00 am
RNS
Farxiga met primary endpoint in landmark Phase III
19 Aug 2019 7:00 am
RNS
Directorate Change
14 Aug 2019 7:00 am
RNS
Lynparza Phase III PAOLA-1 trial met primary endpo
  7:00 am
RNS
Calquence granted US Breakthrough Therapy Designat
09 Aug 2019 9:28 am
RNS
Amendment: Tagrisso significantly improves overall
  7:00 am
RNS
Tagrisso significantly improves overall survival
07 Aug 2019 7:00 am
RNS
Lynparza Phase III PROfound trial in HRR*
05 Aug 2019 7:00 am
RNS
Forxiga label updated in the EU in type-2 diabetes
01 Aug 2019 3:00 pm
RNS
Total Voting Rights
25 Jul 2019 7:00 am
RNS
AZN: H1 2019 Results
15 Jul 2019 7:00 am
RNS
Update on US regulatory decision for Farxiga
12 Jul 2019 7:00 am
RNS
Imfinzi granted US Orphan Drug Designation for
01 Jul 2019 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Forxiga receives positive EU CHMP opinion for
  7:00 am
RNS
Fasenra receives positive EU CHMP opinion for self
27 Jun 2019 7:00 am
RNS
Imfinzi improves overall survival at interim
19 Jun 2019 7:00 am
RNS
Breztri Aerosphere (PT010) approved in Japan for
  7:00 am
RNS
Lynparza approved in Japan for 1st-line
  7:00 am
RNS
Bevespi Aerosphere approved by the Japanese
18 Jun 2019 7:00 am
RNS
Lynparza approved in the EU for 1st-line
17 Jun 2019 7:00 am
RNS
Calquence significantly prolonged the time patient
12 Jun 2019 4:45 pm
RNS
Publication of a Prospectus
06 Jun 2019 7:00 am
RNS
Calquence Phase III ELEVATE-TN trial met primary
05 Jun 2019 12:36 pm
EQS
AstraZeneca: Where has all the cash gone?
03 Jun 2019 3:00 pm
RNS
Block listing Interim Review
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t